Webinar recap
The third installment of the All Welcome Webinar Series reviewed a year of enhancements across Nova, Apollo, and the drug models, then looked ahead to where precision dosing would expand next.
One update answered a frequent question from pharmacist users: whether to cap creatinine clearance at 150 mL/min when dosing adult vancomycin with a model. An analysis of 4,759 patients across 22 hospitals found the answer depends on the model. The Thomson model performed better with the cap, while the Carreno model, used for patients with a BMI of 40 or higher, performed better without it. Nova’s steady-state predictions were also updated to account for loading doses, giving a clearer picture of exposure in the first 24 to 48 hours, when early target attainment matters most for critically ill patients.
In Apollo, new a priori and a posteriori model comparisons showed how well each vancomycin model predicted exposures for a given population, before and after levels were drawn, measured by accuracy and bias. Case examples showed that the best-performing model differed between health systems, and between a hospital’s overall population and its patients with severe obesity.
The roadmap covered new drug module areas, including azole antifungals, solid organ transplant immunosuppressants, and biologics for inflammatory bowel disease, each with workflow features for its own challenges, such as IV-to-PO transitions and outpatient dosing. It also outlined plans to extend Nova beyond drug levels, into biomarker-guided dosing and pharmacogenomic-informed dosing.
